Home > Compound List > Product Information
5-Methoxytryptamine_Molecular_structure_CAS_608-07-1)
Click picture or here to close

5-Methoxytryptamine

Catalog No. 286583 Name Sigma Aldrich
CAS Number 608-07-1 Website http://www.sigmaaldrich.com
M. F. C11H14N2O Telephone 1-800-521-8956
M. W. 190.24166 Fax
Purity 97% Email
Storage Chembase ID: 34025

SYNONYMS

Title
5-甲氧基色胺
IUPAC name
2-(5-methoxy-1H-indol-3-yl)ethan-1-amine
IUPAC Traditional name
5 methoxytryptamine
Synonyms
3-(2-Aminoethyl)-5-methoxyindole
5-MOT
5-Methoxyindole-3-ethanamine
2-(5-Methoxyindol-3-yl)ethylamine
Deacetylmelatonin
NSC 56422

DATABASE IDS

CAS Number 608-07-1
EC Number 210-153-7
PubChem SID 24857245
MDL Number MFCD00005662
Beilstein Number 145587

PROPERTIES

Empirical Formula (Hill Notation) C11H14N2O
Purity 97%
Gene Information human ... HTR1A(3350), HTR2A(3356), HTR2C(3358)rat ... Htr2a(29595), Htr2c(25187), Htr7(65032)
Melting Point 121-123 °C(lit.)
GHS Pictograms GHS07
GHS Signal Word Warning
GHS Hazard statements H302
European Hazard Symbols Harmful Harmful (Xn)
MSDS Link Download
Personal Protective Equipment dust mask type N95 (US), Eyeshields, Gloves
Risk Statements 22
RTECS NL4059000
Safety Statements 36
German water hazard class 3

DETAILS

Description (English)
Packaging
1 g in glass bottle
100 mg in glass bottle
Application
Reactant for preparation of:
• Carboline disaccharide domain of shishijimicin A1
• Melatonin analogs for the reduction of intraocular pressure2
• 5-HT4 receptor ligands3
• inhibitors of sortase A and isocitrate lyase4
• Therapeutic agents for treatment of ischemia/reperfusion (I/R) injury5
• Aurora and epidermal growth factor receptor kinase inhibitors6
• Agents for the treatment of human papillomavirus infection7
• Manzamine analogues for the control of neuroinflammation and cerebral infections8
• Inhibitors of pro-inflammatory cytokines9
• Tacrine-melatonin hybrids as multifunctional agents for alzheimer′s disease10
Description (简体中文)
包装
1 g in glass bottle
100 mg in glass bottle
Application
Reactant for preparation of:
• Carboline disaccharide domain of shishijimicin A1
• Melatonin analogs for the reduction of intraocular pressure2
• 5-HT4 receptor ligands3
• inhibitors of sortase A and isocitrate lyase4
• Therapeutic agents for treatment of ischemia/reperfusion (I/R) injury5
• Aurora and epidermal growth factor receptor kinase inhibitors6
• Agents for the treatment of human papillomavirus infection7
• Manzamine analogues for the control of neuroinflammation and cerebral infections8
• Inhibitors of pro-inflammatory cytokines9
• Tacrine-melatonin hybrids as multifunctional agents for alzheimer′s disease10

REFERENCES